Key result
CRISPR/Cas technology offers a promising gene editing approach for treating human viral infections and developing vaccines.
Why the study?
Viral infections presenting substantial public health risks, such as COVID-19, have limited efficacy with current prophylactic and therapeutic techniques, warranting novel approaches like CRISPR/Cas technology.
CRISPR/Cas technology offers a promising gene editing approach to overcome the limitations of conventional methods in managing viral infections, including COVID-19.
Should not yet change antiviral practice; leaves open clinical translation of Cas9/12/13 systems.
The CRISPR/Cas system, identified as a type of bacterial adaptive immune system, have attracted significant attention due to its remarkable ability to precisely detect and eliminate foreign genetic material and nucleic acids. Expanding upon these inherent capabilities, recent investigations have unveiled the potential of reprogrammed CRISPR/Cas 9, 12, and 13 systems for treating viral infections associated with human diseases, specifically targeting DNA and RNA viruses, respectively. Of particular interest is the RNA virus responsible for the recent global outbreak of coronavirus disease 2019 (COVID-19), which presents a substantial public health risk, coupled with limited efficacy of current prophylactic and therapeutic techniques. In this regard, the utilization of CRISPR/Cas technology offers a promising gene editing approach to overcome the limitations of conventional methods in managing viral infections. This comprehensive review provides an overview of the latest CRISPR/Cas-based therapeutic and vaccine strategies employed to combat human viral infections. Additionally, we discuss significant challenges and offer insights into the future prospects of this cutting-edge gene editing technology.
No takes yet. Share an insight, caveat, or question.
Zahedipour et al. (2024) conducted a review in viral infections. CRISPR/Cas technology was evaluated. CRISPR/Cas technology offers a promising gene editing approach for treating human viral infections and developing vaccines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: